For medical device registration in the United States, on-site audits, also known as inspections, are not always required as part of the initial registration process. The U.S. Food and Drug Administration (FDA) primarily relies on the submission of comprehensive documentation and data to assess compliance with regulatory requirements. This includes technical files, quality management system (QMS) documentation, clinical trial results (if applicable), and other relevant information.
However, the FDA reserves the right to conduct inspections of manufacturing facilities and other establishments as part of its regulatory oversight. These inspections may occur either pre-approval (before granting market authorization) or post-approval to verify compliance with FDA regulations, including the Quality System Regulation (QSR) outlined in 21 CFR Part 820.
Factors influencing the need for on-site audits include:
Device Classification: Higher-risk devices (Class II and III) are more likely to undergo inspections compared to lower-risk devices (Class I).
Submission Type: Submissions requiring premarket approval (PMA) or significant clinical data may prompt FDA to conduct facility inspections to assess manufacturing practices and ensure data integrity.
Quality System Compliance: Manufacturers must demonstrate adherence to QSR through documentation and may be subject to inspection to verify compliance with these standards.
Post-Market Surveillance: FDA may conduct inspections post-market to monitor ongoing compliance, investigate complaints, or assess changes to the device or manufacturing processes.
Manufacturers should be prepared for potential inspections by maintaining a state of readiness, ensuring facilities comply with FDA regulations, and facilitating open communication with FDA inspectors. While on-site audits are not universally required for initial registration, understanding and fulfilling FDA's expectations for compliance can help expedite the approval process and ensure continued market access for medical devices in the United States.
Contact Us:
Whatsapp or Wechat:+86 15816864648;email address:hito.lin@grzan.cn